Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07823790) titled 'ONO-4915 in Patients With Primary Sjogren's Disease' on Sept. 3.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Ono Pharmaceutical Co., Ltd.

Condition: Sjogren's Disease

Intervention: Drug: ONO-4915

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 2026

Target Sample Size: 60

To know more, visit https://clinicaltrials.gov/study/NCT07823790

Disclaimer: Curated by HT Syndication....